All the news Showing 10 of 102 articles from: Treatment outcomesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C reduces cardiovascular risk Keith Alcorn / 20 April 2017 Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice ... Optimism About HCV Treatment Comes With Caveats Medscape / 22 March 2017 Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... Curing hepatitis C reduces the risk of diabetes & kidney failure in people with HIV/HCV co-infection Keith Alcorn / 01 February 2017 Curing hepatitis C infection substantially reduces the risk of developing type 2 diabetes in people with HIV/hepatitis C virus (HCV) co-infection, but does not reduce the risk of cardiovascular disease, ... Curing hepatitis C reduces liver-related complications and death Liz Highleyman / 23 January 2017 People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to people who were not successfully treated, according to research presented at the 2016 ... Real-world studies show 8-week sofosbuvir/ledipasvir course just as effective as 12-week course for genotype 1 patients without cirrhosis Keith Alcorn / 02 December 2016 An 8-week course of treatment with sofosbuvir/ledipasvir is just as effective as a 12-week course of treatment in people without cirrhosis, including those with HIV/hepatitis C virus (HCV) co-infection, and could significantly reduce ... Real-world responses to HCV treatment among US veterans match best clinical trial results Keith Alcorn / 14 November 2016 Direct-acting antiviral (DAA) treatment is curing people of hepatitis C infection in clinics at similar rates to those seen in clinical trials, and there don’t seem to be major differences between drug regimens, ... AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... 100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks Liz Highleyman / 05 October 2016 A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis ... Risk of reinfection is a concern after successful hepatitis C treatment Liz Highleyman / 28 September 2016 People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) – achieving cure rates similar to those of the population as a whole – but some people are reinfected ... ← Prev1...45678...11Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive